<div id="readability-page-1"><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>Eli Lilly and Company (NYSE:LLY - Free Report) - Zacks Research boosted their Q4 2025 earnings per share estimates for Eli Lilly and Company in a research note issued on Tuesday, November 18th. Zacks Research analyst Team now expects that the company will earn $7.00 per share for the quarter, up from their previous estimate of $6.83. The consensus estimate for Eli Lilly and Company's current full-year earnings is $23.48 per share. Zacks Research also issued estimates for Eli Lilly and Company's Q1 2026 earnings at $6.61 EPS, Q2 2026 earnings at $7.94 EPS, Q3 2026 earnings at $8.84 EPS, Q4 2026 earnings at $8.34 EPS, FY2026 earnings at $31.73 EPS, Q1 2027 earnings at $9.35 EPS, Q2 2027 earnings at $9.64 EPS, Q3 2027 earnings at $10.73 EPS and FY2027 earnings at $40.15 EPS.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, beating analysts' consensus estimates of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 earnings per share.  Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS.</p><ul><li>Down 45% Year-to-Date, Novo Nordisk Ignites a Price War</li></ul><p>Other equities research analysts have also recently issued reports about the stock. Weiss Ratings  reiterated a &#34;hold (c+)&#34; rating on shares of Eli Lilly and Company in a research report on Wednesday, October 8th. Hsbc Global Res upgraded shares of Eli Lilly and Company from a &#34;moderate sell&#34; rating to a &#34;hold&#34; rating in a report on Wednesday, August 27th. Berenberg Bank  reissued a &#34;hold&#34; rating and issued a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research report on Wednesday, September 17th. Erste Group Bank upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research report on Tuesday, October 14th. Finally, Leerink Partnrs raised Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Monday, November 10th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have issued  a Buy rating and seven have issued  a Hold rating to the company's stock. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $1,027.95.</p><p><b>Check Out Our Latest Stock Report on LLY</b></p><h2>Eli Lilly and Company Stock Up 1.8%</h2><ul><li>Healthcare Rotation Underway: 3 Stocks Leading the Charge</li></ul><p>Shares of LLY opened at $1,048.90 on Thursday. The company's 50-day moving average price is $844.09 and its 200 day moving average price is $784.22. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,055.59. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a market cap of $991.61 billion, a P/E ratio of 68.56, a price-to-earnings-growth ratio of 1.21 and a beta of 0.43. </p><h2>Institutional Investors Weigh In On Eli Lilly and Company</h2><p>Large investors have recently bought and sold shares of the stock. Sumitomo Mitsui Financial Group Inc. purchased a new stake in  Eli Lilly and Company during the second quarter worth $27,000.  Wealth Preservation Advisors LLC acquired a new position in shares of  Eli Lilly and Company during the 1st quarter worth $27,000.  Evolution Wealth Management Inc. acquired a new position in shares of  Eli Lilly and Company during the 2nd quarter worth $29,000.  Steph &amp; Co. boosted its position in shares of  Eli Lilly and Company by 290.0% in the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock worth $30,000 after buying an additional 29 shares in the last quarter.  Finally, 10Elms LLP grew its stake in  Eli Lilly and Company by 33.3% in the 3rd quarter. 10Elms LLP now owns 40 shares of the company's stock valued at $31,000 after acquiring an additional 10 shares during the last quarter. Hedge funds and other institutional investors own  82.53% of the company's stock. </p><h2>Eli Lilly and Company Announces Dividend</h2><p>The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Stockholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company's dividend payout ratio (DPR) is presently 29.35%. </p><h2>Eli Lilly and Company Company Profile</h2> (Get Free Report)<p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><h2>Read More</h2><ul><li>Five stocks we like better than Eli Lilly and Company</li><li>What Investors Need to Know to Beat the Market</li><li>Applied Materials: Up 40% in 2025 With Room to Run Long-Term</li><li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025 </li><li>onsemi Places a $6 Billion Bet on Its Own Stock</li><li>5 discounted opportunities for dividend growth investors</li><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Zacks Research has raised its Q4 2025 earnings per share estimate for Eli Lilly to $7.00, up from $6.83. The consensus full-year earnings estimate is $23.48 per share. Eli Lilly's recent earnings beat expectations, reporting $7.02 EPS against a $6.42 estimate, with revenue of $17.60 billion. The stock has a consensus rating of "Moderate Buy" and an average target price of $1,027.95. Institutional investors hold 82.53% of the stock.</p>

Zacks Research Has Bullish Forecast for LLY Q4 Earnings